Cardiff Oncology, Inc. (CRDF) Stock Forecast
CRDF analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.83 / 5 from 6 analysts
- Price target
- $5.81 average of analyst targets
- Upside to target
- +546.0% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.14
- 52-week range
- $0.81 – $3.21
CRDF analyst ratings
6 analystsNumber of analysts at each rating.
CRDF price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CRDF earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.14 | −$0.12 | −$0.17 | +23.5% | 4 |
| Current fiscal year (2026) | −$0.56 | −$0.60 | −$0.50 | −$0.69 | +18.5% | 4 |
| Next fiscal year (2027) | −$0.54 | −$0.76 | −$0.33 | −$0.56 | +4.9% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CRDF revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $86,430 | $0 | $150,000 | −28.0% | 7 |
| Current fiscal year (2026) | $295,140 | $0 | $445,000 | −50.2% | 7 |
| Next fiscal year (2027) | $320,830 | $0 | $725,000 | +8.7% | 6 |
CRDF EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CRDF revenue: reported and forecast
CRDF EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.17 | −$0.13 | −$0.13 | −$0.13 | −22.8% | 4 up · 0 down |
| Current fiscal year (2026) | −$0.69 | −$0.69 | −$0.55 | −$0.56 | −$0.56 | −18.1% | 4 up · 0 down |
| Next fiscal year (2027) | −$0.81 | −$0.81 | −$0.63 | −$0.60 | −$0.54 | −34.1% | 4 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CRDF earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CRDF beat in 8 of 12.
What analysts expect from CRDF
6 analysts cover Cardiff Oncology; their consensus rating is buy (3.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.81, 546.0% above the latest close of $0.90. Analysts expect earnings of −$0.56 per share for 2026, +18.5% from a year earlier. For 2027 the average estimate is −$0.54 per share on revenue of $0.3 million. Cardiff Oncology beat the EPS estimate in 8 of the last 12 quarters.
Related: CRDF income statement, CRDF key metrics, CRDF chart. See the CRDF stock overview for the latest quote and news.
CRDF forecast FAQ
What is Cardiff Oncology's price target?
The average analyst price target for Cardiff Oncology is $5.81, 546.0% above the latest close of $0.90.
Is Cardiff Oncology a buy, hold or sell?
Of 6 analysts covering Cardiff Oncology, 2 rate it a strong buy, 1 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Cardiff Oncology's EPS forecast?
Analysts forecast −$0.56 per share for 2026 (range −$0.60 to −$0.50); for 2027 the estimate is −$0.54.
What is Cardiff Oncology's revenue forecast?
The average revenue estimate for 2026 is $0.3 million, growth of −50.2%; for 2027 it is $0.3 million.
When does Cardiff Oncology report earnings?
Cardiff Oncology is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-0.14.
Does Cardiff Oncology usually beat earnings estimates?
Cardiff Oncology reported EPS at or above the analyst estimate in 8 of the last 12 quarters.